Pembrolizumab-induced Stevens-Johnson syndrome in advanced squamous cell carcinoma of the lung:A case report and review of literature  

作　　者：Jing-Yi Wu Kai Kang Jing Yi Bin Yang 

机构地区：[1]Department of Thoracic Oncology,Hubei Cancer Hospital,Tongji Medical College,Huazhong University of Science and Techonology,Wuhan 430000,Hubei Province,China [2]Department of Thoracic Oncology Surgery,Hubei Cancer Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430070,Hubei Province,China

出　　处：《World Journal of Clinical Cases》2022年第18期6110-6118,共9页世界临床病例杂志

摘　　要：BACKGROUND For advanced lung squamous cell carcinoma,immune checkpoint inhibitors(ICIs)have been regarded as one of the optimal therapies.While immune-related adverse events(ir AEs)are common in ICI treatment,cutaneous toxicities are among the most common ir AEs.Most immune-related skin toxicity grades are low,and the prognosis is good.However,Stevens-Johnson syndrome(SJS)is a rare but extremely severe cutaneous adverse drug reaction with high mortality.CASE SUMMARY We report a rare case of SJS induced by pembrolizumab.The case involved a 68-year-old female who was diagnosed with advanced squamous cell carcinoma of the lung.SJS appeared after one cycle of immunotherapy combined with chemotherapy.After treatment with prednisone hormone symptoms,antiinfection,gamma globulin,and antipruritic agents,the skin toxicity of the patients gradually decreased and eventually disappeared.Although the antitumor treatment was stopped due to serious adverse reactions,the tumor of the patient remained stable for nearly half a year after one cycle of immune therapy combined with chemotherapy,which also corroborates the delayed effect of immunotherapy.CONCLUSION We believe our report can provide some references for the treatment of SJS and the treatment of immune-related adverse reactions.

关 键 词：Pembrolizumab Stevens-Johnson syndrome Advanced squamous cell carcinoma LUNG Immune-related adverse events Case report 

分 类 号：R734.2[医药卫生—肿瘤]